JP Morgan Maintains Neutral on Silk Road Medical, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus maintains a Neutral rating on Silk Road Medical (NASDAQ:SILK) and raises the price target from $19 to $21.

May 01, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Robbie Marcus maintains a Neutral rating on Silk Road Medical and raises the price target from $19 to $21.
The increase in price target by a reputable analyst like Robbie Marcus from JP Morgan suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term positive impact on SILK's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100